BlueStone Venture Partners

BlueStone Venture Partners is a venture capital firm established in 2018, initially launched in Tucson, Arizona, and currently based in Santa Fe, New Mexico. The firm specializes in providing strategic capital and support to early-stage life science companies, primarily focusing on Series A and Series B funding rounds. Its investment interests encompass a range of sectors, including medical devices, health information technology, advanced materials, molecular diagnostics, and biopharma. The firm aims to foster innovation and growth within these industries by partnering with entrepreneurial companies.

Andrew More

Director

Thomas Nickoloff

Co-Founder and Managing Director

Past deals in Arizona

GT Medical Technologies

Series C in 2023
GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

GT Medical Technologies

Series B in 2020
GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Pyx Health

Series A in 2020
Pyx Health, Inc., established in 2017 and headquartered in Tucson, Arizona, specializes in developing a mobile solution that connects with individuals outside traditional healthcare settings to reduce loneliness and social isolation. The company's flagship product, Pyx Health, combines artificial intelligence and human interventions to provide critical and timely support, addressing social determinants of health. Central to this platform is Pyxir, an endearing chatbot personality that accompanies users throughout their healthcare journey, fostering trusted companionship and promoting healthy interaction within the app.

GT Medical Technologies

Series A in 2019
GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.